I
I

Financials • ImageneBio

IMA

ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
12/2024
4
-35
-37
L
-161
L
-4
-
-21
0
7
-21
L

To see all financials—including updated, you must be Premium.